AU4165493A - Sustained release pharmaceutical composition - Google Patents

Sustained release pharmaceutical composition

Info

Publication number
AU4165493A
AU4165493A AU41654/93A AU4165493A AU4165493A AU 4165493 A AU4165493 A AU 4165493A AU 41654/93 A AU41654/93 A AU 41654/93A AU 4165493 A AU4165493 A AU 4165493A AU 4165493 A AU4165493 A AU 4165493A
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
sustained release
release pharmaceutical
sustained
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU41654/93A
Other versions
AU668174B2 (en
AU668174C (en
Inventor
Mark Christopher Fisher
Angelo Mario Morella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
FH Faulding and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FH Faulding and Co Ltd filed Critical FH Faulding and Co Ltd
Priority claimed from AU41654/93A external-priority patent/AU668174C/en
Priority to AU41654/93A priority Critical patent/AU668174C/en
Priority to NZ24816693A priority patent/NZ248166A/en
Priority to CN 94115992 priority patent/CN1107331A/en
Publication of AU4165493A publication Critical patent/AU4165493A/en
Publication of AU668174B2 publication Critical patent/AU668174B2/en
Publication of AU668174C publication Critical patent/AU668174C/en
Application granted granted Critical
Priority to CNA021219125A priority patent/CN1468597A/en
Assigned to MAYNE PHARMA INTERNATIONAL PTY LTD reassignment MAYNE PHARMA INTERNATIONAL PTY LTD Request to Amend Deed and Register Assignors: F.H. FAULDING & CO. LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

AU41654/93A 1993-06-30 1993-06-30 Sustained release pharmaceutical composition Expired AU668174C (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU41654/93A AU668174C (en) 1993-06-30 Sustained release pharmaceutical composition
NZ24816693A NZ248166A (en) 1993-06-30 1993-07-16 Sustained-release pharmaceutical pellet composition comprising a core and a coating which is partially soluble at a high acidic ph, the active ingredient being absorbable from the intestine over an extended time
CN 94115992 CN1107331A (en) 1993-06-30 1994-06-30 Sustained release pharmaceutical composition
CNA021219125A CN1468597A (en) 1993-06-30 2002-05-24 Continuous released medical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU41654/93A AU668174C (en) 1993-06-30 Sustained release pharmaceutical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU47732/90A Addition AU617573C (en) 1989-01-06 1990-01-05 Sustained release pharmaceutical composition

Publications (3)

Publication Number Publication Date
AU4165493A true AU4165493A (en) 1995-02-16
AU668174B2 AU668174B2 (en) 1996-04-26
AU668174C AU668174C (en) 1997-09-25

Family

ID=

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143328A (en) * 1993-07-27 2000-11-07 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US6294195B1 (en) 1991-12-24 2001-09-25 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US7846476B2 (en) 2001-05-02 2010-12-07 Purdue Pharma L.P. Once-a-day oxycodone formulations
US9655893B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-a-day oxycodone formulations
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US10022368B2 (en) 2000-10-30 2018-07-17 Purdue Pharma L.P. Methods of manufacturing oral formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294195B1 (en) 1991-12-24 2001-09-25 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6572885B2 (en) 1991-12-24 2003-06-03 Euro-Celtique, S.A. Orally administrable opioid formulations having extended duration of effect
US6143328A (en) * 1993-07-27 2000-11-07 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US6399096B1 (en) 1995-09-22 2002-06-04 Euro-Celtique S.A. Pharmaceutical formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10076516B2 (en) 1999-10-29 2018-09-18 Purdue Pharma L.P. Methods of manufacturing oral dosage forms
US10022368B2 (en) 2000-10-30 2018-07-17 Purdue Pharma L.P. Methods of manufacturing oral formulations
US9655894B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-A day oxycodone formulations
US9655893B2 (en) 2001-05-02 2017-05-23 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7846476B2 (en) 2001-05-02 2010-12-07 Purdue Pharma L.P. Once-a-day oxycodone formulations
US10660886B2 (en) 2001-05-02 2020-05-26 Purdue Pharma L.P. Oxycodone formulations

Also Published As

Publication number Publication date
AU668174B2 (en) 1996-04-26
CN1107331A (en) 1995-08-30
CN1468597A (en) 2004-01-21
NZ248166A (en) 1995-04-27

Similar Documents

Publication Publication Date Title
AU6216296A (en) Pharmaceutical compositions
AUPN411195A0 (en) Medicinal composition
AU6740298A (en) Pharmaceutical composition
AU7590096A (en) Drug composition
AU3716193A (en) Pharmaceutical compositions
AU5155096A (en) Pharmaceutical composition
GB9316580D0 (en) Pharmaceutical composition
AU5274096A (en) Pharmaceutical compositions
AU2531295A (en) Pharmaceutical composition
AU5943990A (en) Sustained release pharmaceutical compositions
AU9343098A (en) Pharmaceutical composition
AU7275894A (en) Imidazolylalkylamine derivative and pharmaceutical composition thereof
AU2392492A (en) Pharmaceutical composition
CA2100836A1 (en) Pharmaceutical Composition
AU7661994A (en) Photopolymerisable composition
AU6690394A (en) Imidazolylquinoxalinedione derivative and pharmaceutical composition thereof
GB9318880D0 (en) Pharmaceutical composition
AU668174C (en) Sustained release pharmaceutical composition
AU4165493A (en) Sustained release pharmaceutical composition
AU6814496A (en) Pharmaceutical composition
AU3528593A (en) Pharmaceutical composition
AUPM303393A0 (en) Pharmaceutical composition
AU617573C (en) Sustained release pharmaceutical composition
AU741226C (en) Pharmaceutical composition
AU723097C (en) Pharmaceutical composition